Extension Statement for CONSORT-C: Improving Reporting Standards and Influence in Pediatric and Adolescent Research - Takeaways - MDSpire

Extension Statement for CONSORT-C: Improving Reporting Standards and Influence in Pediatric and Adolescent Research

  • By

  • Ami Baba

  • Maureen Smith

  • Beth K. Potter

  • An-Wen Chan

  • David Moher

  • Alene Toulany

  • Amanda Doherty-Kirby

  • Begonya Nafria Escalera

  • Catherine Stratton

  • Chris Gale

  • Colin Macarthur

  • Diane Purper-Ouakil

  • Edmund Juszczak

  • Eyal Cohen

  • Giorgio Reggiardo

  • Jennifer Preston

  • Jérémie F. Cohen

  • Julia Upton

  • Karel Allegaert

  • Katelynn Boerner

  • Kayur Mehta

  • Kim An Nguyen

  • Kimberly Courtney

  • Lisa Hartling

  • Menelaos Konstantinidis

  • Michal Odermarsky

  • Nancy J. Butcher

  • Niina Kolehmainen

  • Patricia E. Longmuir

  • Peter J. Gill

  • Piet Leroy

  • Reinhard Feneberg

  • Ramesh Poluru

  • Shaun K. Morris

  • Stefan J. Friedrichsdorf

  • Tanya Chute Nagy

  • Terry P. Klassen

  • Thierry Lacaze-Masmonteil

  • Wes Onland

  • Martin Offringa

  • April 1, 2026

  • 0 min

Share

  • 1

    Pediatric randomized controlled trials (RCTs) are often underreported and underrepresented, leading to a lack of quality evidence for children and adolescents.

  • 2

    The CONSORT-C 2026 extension provides specific reporting guidelines for pediatric RCTs to improve transparency and quality in research.

  • 3

    The pediatric population is diverse, necessitating unique considerations in trial design, consent processes, and reporting standards.

  • 4

    The development of CONSORT-C involved collaboration with young people and family caregivers to ensure relevant and practical guidance.

  • 5

    Improving reporting standards in pediatric RCTs is essential for enhancing health care decisions and outcomes for infants, children, and adolescents.

Original Source(s)

Related Content